<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00309413</url>
  </required_header>
  <id_info>
    <org_study_id>CBD-PT 04-153</org_study_id>
    <nct_id>NCT00309413</nct_id>
  </id_info>
  <brief_title>A Clinical Trial on the Antipsychotic Properties of Cannabidiol</brief_title>
  <official_title>A Placebo-Controlled Randomized Cross-Over Clinical Trial on the Antipsychotic Properties of the Endocannabinoid Modulator Cannabidiol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Coordinating Centre for Clinical Trials Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether cannabidiol, a herbal cannabinoid, is
      effective in the treatment of acute schizophrenic or schizophreniform psychosis in a
      placebo-controlled, randomized double-blind study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite recent advances in the treatment of schizophrenia and schizophreniform disorders,
      there is still a need to develop efficient and better tolerated psychopharmacological
      approaches to this group of diseases. The endogenous cannabinoid system provides a promising
      target in the pharmacotherapy of these disorders. This approach is based upon recent findings
      indicating that the human endogenous cannabinoid system is significantly involved in the
      pathogenesis of schizophrenia and that cannabidiol is effective in treating acute psychotic
      symptoms of schizophrenic patients. We will investigate cannabidiol versus placebo in a
      randomized, double blind design with extensive safety measures.

      The primary hypothesis to be tested is that Cannabidiol is expected to be superior to placebo
      in the treatment of acute schizophrenic and schizophreniform psychoses with regard to its
      antipsychotic efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BPRS</measure>
    <time_frame>2 x 2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PANSS, EPS, Prolactin, ECG etc.</measure>
    <time_frame>2 x 2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Psychotic Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cannabidiol/Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo/Cannabidiol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo/Cannabidiol</intervention_name>
    <description>600 mg/day, oral, capsules, 2 weeks, than cross-over</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol/Placebo</intervention_name>
    <description>600 mg/day, oral, capsules, 2 weeks, than cross-over</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV Diagnosis of schizophrenic or schizophreniform psychosis

          -  Minimal initial score of 36 in the BPRS total score and a minimum of 12 in the BPRS
             Psychosis Cluster, including items 4 (conceptional disorganisation), 8 (exaggerated
             self-esteem), 12 (hallucinatory behaviour), and 15 (unusual thought content)

          -  Exclusion of pregnancy in female subjects through negative Î²-HCG test

        Exclusion Criteria:

          -  Lack of accountability

          -  Pregnancy or risk of pregnancy or lactation.

          -  Other relevant interferences of axis 1 according to diagnostic evaluation through MINI
             including undifferentiated residual forms of schizophrenia.

          -  Treatment with depot-antipsychotics during the last three months.

          -  Severe internal or neurological illness, especially cardiovascular, renal, advanced
             respiratory, haematological or endocrinological failures. Positive Hepatitis-serology.

          -  QTc-elongation.

          -  Acute suicidal tendency of or hazard to others by the patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>F. Markus Leweke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cologne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cologne, Dept. of Psychiatry and Psychotherapy</name>
      <address>
        <city>Cologne</city>
        <state>NRW</state>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2006</study_first_submitted>
  <study_first_submitted_qc>March 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2006</study_first_posted>
  <last_update_submitted>July 23, 2008</last_update_submitted>
  <last_update_submitted_qc>July 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>F. Markus Leweke, M.D.</name_title>
    <organization>University of Cologne</organization>
  </responsible_party>
  <keyword>Schizophrenia and Disorders with Psychotic Features</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

